Priorix

Product Details

PRIORIX (Measles, Mumps, and Rubella Vaccine, Live) is a suspension for subcutaneous injection. PRIORIX is supplied as a sterile, lyophilized antigen component which is reconstituted at the time of use with the accompanying sterile water diluent. The lyophilized antigen component is a whitish to slightly pink powder.

PRIORIX contains the Schwarz strain of live attenuated measles virus, the RIT 4385 strain of live attenuated mumps virus (derived from the Jeryl Lynn strain), both propagated in chick‑embryo fibroblasts from embryonated eggs of specific pathogen-free flocks and the Wistar RA 27/3 strain of live attenuated rubella virus propagated in MRC-5 human diploid cells. The 3 virus strains are cultured in media containing amino acids, a small amount of neomycin sulfate and bovine serum albumin and are stabilized after multiple washing steps in media free from antibiotics and albumin. The attenuated measles, mumps and rubella viruses are then mixed with a stabilizer prior to lyophilization.

After reconstitution, each approximately 0.5-mL dose contains not less than 3.4 log10 Cell Culture Infective Dose 50% (CCID50) of measles virus, 4.2 log10 CCID50 of mumps virus, and 3.3 log10 CCID50 of rubella virus. Each dose also contains 32 mg of anhydrous lactose, 9 mg of sorbitol, 9 mg of amino acids, and 8 mg of mannitol. Each dose may also contain residual amounts of neomycin sulphate (≤25 mcg), ovalbumin (≤60 ng), and bovine serum albumin (≤50 ng), from the manufacturing process. After reconstitution, PRIORIX is a clear peach- to fuchsia pink-colored suspension.